Literature DB >> 16361713

Association between alopecia areata and HLA Class I and II in Turkey.

Cihangir Aliagaoglu1, Ibrahim Pirim, Mustafa Atasoy, Nilnur Egerci, Akin Aktas.   

Abstract

HLA class I and II alleles have been described in patients with alopecia areata (AA). As in other immune mediated diseases, the HLA alleles associated with AA may influence the patient's ability to respond to immune challenges from both self and non-self antigens and can offer clues to the cause, prognosis, and potential therapy for the disease. The aim of this study was to determine which HLA class I and II alleles are associated with Turkish alopecia areata patients. Sixty-three patients with AA, alopecia totalis, or alopecia universalis were included in this study and compared with seventy-six healthy transplant donors. HLA DNA typing was performed by the PCR/SSP method. The frequency of HLA-B62 was significantly higher in patients than in controls. HLA-A2, HLA-A24, HLA-B35, HLA-DRB1*11, and HLA-DRB1*15 were significantly less common in patients than in the control group.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16361713     DOI: 10.1111/j.1346-8138.2005.tb00830.x

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  3 in total

1.  The Immunogenetics of Alopecia areata.

Authors:  Fateme Rajabi; Fahimeh Abdollahimajd; Navid Jabalameli; Mansour Nassiri Kashani; Alireza Firooz
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Association analysis of the HLA-C gene in Japanese alopecia areata.

Authors:  Yuko Haida; Shigaku Ikeda; Atsushi Takagi; Etsuko Komiyama; Tomotaka Mabuchi; Akira Ozawa; Jerzy K Kulski; Hidetoshi Inoko; Akira Oka
Journal:  Immunogenetics       Date:  2013-04-16       Impact factor: 2.846

Review 3.  HLA-DRB1 polymorphisms and alopecia areata disease risk: A systematic review and meta-analysis.

Authors:  Conghua Ji; Shan Liu; Kan Zhu; Hongbin Luo; Qiushuang Li; Ying Zhang; Sijia Huang; Qing Chen; Yi Cao
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.